Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Moleculin Biotech, Inc. (MBRX : NSDQ)

• Company Description    Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $2.24 Daily Weekly Monthly 20 Day Moving Average: 131,727 shares Shares Outstanding: 5.34 (millions) Market Capitalization: $11.95 (millions) Beta: 1.73 52 Week High: $28.61 52 Week Low: $1.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.88% 2.10% 12 Week -42.56% -37.51% Year To Date -32.33% -26.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5300 MEMORIAL DRIVE SUITE 950 - HOUSTON,TX 77007 USA ph: 713-300-5160 fax: - mbrx@jtcir.com http://www.moleculin.com

• General Corporate Information    Officers Walter V. Klemp - Chief Executive Officer and Chairman Jonathan P. Foster - Executive Vice President and Chief Financial Offic Robert George - Director Michael Cannon - Director John Climaco - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 60855D408 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 05/12/26 Share - Related Items Shares Outstanding: 5.34 Most Recent Split Date: 12.00 (0.04:1) Beta: 1.73 Market Capitalization: $11.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 93.78% vs. Previous Quarter: 73.47% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - -1,092.49 ROA 12/31/25 - -60.88 09/30/25 - -143.21 06/30/25 - -152.35 Current Ratio 12/31/25 - 1.41 09/30/25 - 1.39 06/30/25 - 1.15 Quick Ratio 12/31/25 - 1.41 09/30/25 - 1.39 06/30/25 - 1.15 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 4.69 09/30/25 - -13.60 06/30/25 - -5.93 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - 0.00 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©